Global Gemcitabine HCl Market, By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer, Biliary Tract Cancer, Others), Route of Administration (Intravenous), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Global Gemcitabine HCl Market Analysis and Size
The gemcitabine HCl market is expected to witness significant growth during the forecast period. Varied R&D activities are contributing to the growth of the market. Growing cancer cases, especially in females such as breast and ovarian cancer, drives the gemcitabine HCl market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the gemcitabine HCl market in the forecast period 2022-2029. The expected CAGR of global gemcitabine HCl market is tend to be around 7% in the mentioned forecast period. The market was valued at USD 612 million in 2021, and it would grow upto USD 1051.53 mllion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Gemcitabine HCl is the antimetabolite-antineoplastic agent with synthetic pyrimidine nucleoside. It acts by replacing cytidine during DNA replication, due to this arrests tumor growth, new nucleosides cannot be attached to the “faulty” nucleoside and resulting apoptosis in tumor cells. It is the FDA approved agent sold under the brand name “Gemzar”. It can be used with other oncology agents in combination such as paclitaxel, cisplatin and others. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Global Gemcitabine HCl Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer, Biliary Tract Cancer, Others), Route of Administration (Intravenous), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China), Hikma Pharmaceuticals PLC (Japan), Novartis AG (U.S), Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China), Teva Pharmaceutical Industries Ltd. (Israel), HEYER Medical AG (Germany), Biometrix (Netherlands), Smiths Medical (U.S.)
|
|
Market Opportunities
|
|
Global Gemcitabine HCl Market Dynamics
Drivers
- Increasing Influence of Multi-Channel Engagement
The launch of new digital channels developed significant changes among the major market players with regards to maintaining contact with healthcare professionals and increasing the overall reach. Pharmaceutical companies are being compelled to differentiate the new rules of the market with the transition in purchasing power and reduced access to healthcare professionals (HCPs). When it comes to keeping in touch with HCPs and expanding their overall reach, the top companies in the gemcitabine market have seen substantial changes as a result of the advent of new digital channels.
- Increased Clinical Studies and Government Initiatives
Rising awareness about the antidotes and studies that are conducted for development in identifying toxins in snake bites that by government and private companies for better knowledge of these drugs and antidotes is likely to drive the market growth.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global gemcitabine HCl market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This gemcitabine HCl market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gemcitabine HCl market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Gemcitabine HCl Market Scope
The gemcitabine HCl market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Breast Cancer
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Bladder Cancer
- Biliary Tract Cancer
- Others
Route of Administration
- Intravenous
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Gemcitabine HCl Market Regional Analysis/Insights
The gemcitabine HCl market is analysed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the gemcitabine HCl market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increasing infection in geriatric population, and growing population with cardiovascular diseases.
Asia-Pacific dominates the market due to increased prevalence of lung infections and associated diseases and increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Gemcitabine HCl Market Share Analysis
The gemcitabine HCl market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gemcitabine HCl market.
Key players operating in the gemcitabine HCl market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (U.S)
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- HEYER Medical AG (Germany)
- Biometrix (Netherlands)
- Smiths Medical (U.S.)
SKU-